Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Myelodysplastic syndrome (MDS) is clonal disorder characterized by ineffective hematopoiesis and a tendency to evolve into acute myeloid leukemia (AML). Genetic studies have enabled the identification of a set of recurrently mutated genes central to the pathogenesis of MDS, which can be organized into a limited number of cellular processes, including RNA splicing, epigenetic and traditional transcriptional regulation, and signal transduction. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal hematopoiesis to frank MDS, and, ultimately, to secondary AML. This detailed understanding of the molecular landscape of MDS, coupled with the emergence of cost- and time-effective methodologies for DNA sequencing has led to the introduction of genetic studies into the clinical realm. Here, we review recent advances in our genetic understanding of MDS, with a particular focus on the emerging role for mutational data in clinical management as a potential tool to assist in diagnosis, risk stratification, and therapeutic decision-making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · cited 3×
“The WHO has defined various disease subtypes on the basis of the number of dysplastic and cytopenic lineages, the prevalence of blasts, the percentage of ring sideroblasts (RS), and the presence of specific cytogenetic abnormalities.(40) However, given this heavy reliance on morphologic assessment, MDS can be challeng…”
BackgroundMethodInfluentialGenomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Self-citationInternational scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531 · cited 1×
“The acquisition of further mutations drives the progression of CHIP to overt malignancy, as demonstrated by the common clonal origin of paired CHIP and AML samples.(31)”
BackgroundRevised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 2,844
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · cited 1×
“However, not all patients respond to these therapies, with less than 50% achieving hematologic improvement.(58) Given that genes regulating DNA methylation are recurrently mutated in MDS, there has been significant interest in the potential for genetics to identify those who may benefit from HMA therapy.”
BackgroundFrequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020 · cited 2×
“Heterozygous hotspot changes alter isocitrate dehydrogenase enzymatic activity, resulting in the generation of 2-hydroxyglutarate, an oncometabolite that inhibits the activity of numerous targets, including TET2.”
BackgroundDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971 · cited 3×
“5% to 1% per year.(29) CBC, complete blood cell count; CCUS, clonal cytopenias of undetermined significance; CHIP, clonal hematopoiesis of indeterminate potential; MDS, myelodysplastic syndrome; sAML, secondary acute myeloid leukemia.”
BackgroundInfluentialSelf-citationAge-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832 · cited 5×
“However, given that cytopenias, blast count, and morphology are likely closely linked to the genetic makeup of the MDS clone, it follows that prognostic models that include a detailed set of clinical and cytogenetic variables are only modestly improved by the inclusion of mutational data.(11,12) This in-”
BackgroundInfluentialMutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · cited 3×
“The recurrent somatic mutations observed in MDS are not specific for this disease entity; for example, TET2 mutations are prevalent in conditions on the differential diagnosis of MDS, namely AML, MPNs, and MPN/MDS overlap syndromes.(9) Moreover, somatic mutations in MDS-associated genes have been identified in healthy…”
BackgroundClinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627 · cited 5×
“First, as the number of oncogenic mutations increases, patient outcomes progressively worsen.(10,11) Second, in univariate analyses, somatic mutations in certain genes reproducibly predict patient outcomes.”
BackgroundInfluentialSelf-citationLandscape of genetic lesions in 944 patients with myelodysplastic syndromes
Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014) · Leukemia · doi:10.1038/leu.2013.336 · Cited by 1,532 · cited 4×
“marrow failure syndromes with a propensity to evolve into myeloid malignancies.(11,12,26)”
BackgroundInfluentialCohesins: Chromosomal Proteins that Prevent Premature Separation of Sister Chromatids
Michaelis, C., Ciosk, R., & Nasmyth, K. (1997) · Cell · doi:10.1016/s0092-8674(01)80007-6 · Cited by 1,471 · cited 1×
“Cohesin normally functions to align sister chromatids during mitosis; however, mutations do not result in gross aneuploidy.(7,24) Instead, recent studies have shown that cohesin mutations can promote transformation by driving aberrant transcriptional programs, potentially by disrupting this complex’s role in stabilizi…”
BackgroundLenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · cited 1×
“In these patients, treatment with lenalidomide resulted in cytogenetic complete remissions and lower transfusion requirements.(52,53) Lenalidomide binds to the CRL4 E3 ubiquitin ligase, altering its substrate affinity to induce the selective degradation of casein kinase 1A1 (CK1a).”
BackgroundSomatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222 · cited 2×
“Most notably, mutations in the spliceosome gene SF3B1 define a subgroup of patients with RSs and favorable prognosis.(6,15) The marked specificity of this association is reflected in the updated WHO criteria, where, in the presence of cytopenias and dysplasia, detection of an SF3B1 mutation can establish a diagnosis o…”
BackgroundBone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Raaijmakers, M. H. G. P., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., et al. (2010) · Nature · doi:10.1038/nature08851 · Cited by 1,115 · cited 1×
“These variables reflect not only the genetics of the neoplastic clone, but also other potential contributors to MDS biology, such as the microenvironment, which has been shown to contribute to disease pathogenesis in animal models.(50) In light of this, before the routine use of mutational data for MDS prognostication…”
BackgroundSelf-citationAcute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991 · cited 10×
“With the advent of cost- and time-effective sequencing technologies, mutational profiling has also entered the clinical realm, with many centers now including these analyses as part of the routine work-up of patients with MDS.”
BackgroundInfluentialSelf-citationRole of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., et al. (2015) · Nature · doi:10.1038/nature13968 · Cited by 892
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863 · cited 1×
“CK1a is encoded by a gene in the commonly deleted region of chromosome 5 in del(5q) MDS; this creates a therapeutic window for lenalidomidemediated degradation, because further loss of CK1a in the setting of baseline haploinsufficiency leads to p53-mediated apoptosis.(54) Consistent with this, mutations in TP53 are as…”
BackgroundSelf-citationTargeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Clonal Architecture of Secondary Acute Myeloid Leukemia
Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K., Larson, D. E., McLellan, M. D., Dooling, D., Abbott, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106968 · Cited by 775 · cited 7×
“For example, small-molecule inhibitors of mutant isocitrate dehydrogenase enzymes, present in a minority of patients with MDS, have displayed efficacy in preclinical studies of AML.68,69 Moreover, animal models of splicing factor mutations have shown that mutant homozygosity is lethal, whereas in the setting of hetero…”
BackgroundInfluential( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703 · cited 2×
“Heterozygous hotspot changes alter isocitrate dehydrogenase enzymatic activity, resulting in the generation of 2-hydroxyglutarate, an oncometabolite that inhibits the activity of numerous targets, including TET2.”
BackgroundSelf-citationClonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
Young, A. L., Challen, G. A., Birmann, B. M., & Druley, T. E. (2016) · Nature Communications · doi:10.1038/ncomms12484 · Cited by 692
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Graubert, T. A., Shen, D., Ding, L., Okeyo-Owuor, T., Lunn, C. L., Shao, J., Krysiak, K., Harris, C. C., Koboldt, D. C., Larson, D. E., et al. (2012) · Nature Genetics · doi:10.1038/ng.1031 · Cited by 580
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
Kim, E., Ilagan, J. O., Liang, Y., Daubner, G. M., Lee, S. C.-W., Ramakrishnan, A., Li, Y., Chung, Y. R., Micol, J.-B., Murphy, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.006 · Cited by 575
Effect of Mutation Order on Myeloproliferative Neoplasms
Ortmann, C. A., Kent, D. G., Nangalia, J., Silber, Y., Wedge, D. C., Grinfeld, J., Baxter, E. J., Massie, C. E., Papaemmanuil, E., Menon, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412098 · Cited by 562 · cited 2×
“TET2 is an early, clonal mutation as opposed to a late subclonal event,(60) providing evidence that the order of mutation acquisition, not merely the presence of a given mutation, may influence therapeutic responsiveness, as has recently been suggested for MPNs.(62) However, the power of mutational data to predict HMA…”
BackgroundTET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Bejar, R., Lord, A., Stevenson, K., Bar-Natan, M., Pérez-Ladaga, A., Zaneveld, J., Wang, H., Caughey, B., Stojanov, P., Getz, G., et al. (2014) · Blood · doi:10.1182/blood-2014-06-582809 · Cited by 562
Self-citationRecurrent DNMT3A mutations in patients with myelodysplastic syndromes
Walter, M. J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.44 · Cited by 527
Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., te Boekhorst, P., Sanz, G., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 486 · cited 1×
“In these patients, treatment with lenalidomide resulted in cytogenetic complete remissions and lower transfusion requirements.(52,53) Lenalidomide binds to the CRL4 E3 ubiquitin ligase, altering its substrate affinity to induce the selective degradation of casein kinase 1A1 (CK1a).”
BackgroundItzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V, Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Vey, N., Gelsi-Boyer, V, Raynaud, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.71 · Cited by 471
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463
Bejar, R., Stevenson, K. E., Caughey, B. A., Abdel-Wahab, O., Steensma, D. P., Galili, N., Raza, A., Kantarjian, H., Levine, R. L., Neuberg, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7379 · Cited by 441 · cited 2×
“Notably, somatic mutations can predict overall survival independent of clinical prognostic scoring systems, including the IPSS-R (Fig 3).(10,48) However, given that cytopenias, blast count, and morphology are likely closely linked to the genetic makeup of the MDS clone, it follows that prognostic models that include a…”
BackgroundResultSelf-citationSF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Malcovati, L., Karimi, M., Papaemmanuil, E., Ambaglio, I., Jädersten, M., Jansson, M., Elena, C., Gallì, A., Walldin, G., Della Porta, M. G., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633537 · Cited by 434 · cited 2×
“Most notably, mutations in the spliceosome gene SF3B1 define a subgroup of patients with RSs and favorable prognosis.(6,15) The marked specificity of this association is reflected in the updated WHO criteria, where, in the presence of cytopenias and dysplasia, detection of an SF3B1 mutation can establish a diagnosis o…”
BackgroundLandscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes
Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Shiozawa, Y., Kon, A., Alpermann, T., Yoshida, K., et al. (2013) · Blood · doi:10.1182/blood.v122.21.521.521 · Cited by 431
Bejar, R., Stevenson, K. E., Caughey, B., Lindsley, R. C., Mar, B. G., Stojanov, P., Getz, G., Steensma, D. P., Ritz, J., Soiffer, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3381 · Cited by 396 · cited 1×
“In a single-center retrospective study of patients who underwent pretransplant genetic profiling, mutations in TP53 were associated with significantly decreased overall survival.(66) A recent study has replicated the negative prognostic impact of TP53 mutations in the”
BackgroundSelf-citationAdès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 393
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms
Kon, A., Shih, L.-Y., Minamino, M., Sanada, M., Shiraishi, Y., Nagata, Y., Yoshida, K., Okuno, Y., Bando, M., Nakato, R., et al. (2013) · Nature Genetics · doi:10.1038/ng.2731 · Cited by 384 · cited 1×
“Mutually exclusive loss of function nonsense and frameshift mutations in the cohesin components are found in 11% and 17% of low- and high-risk MDS, respectively.(22,23) Cohesin normally functions to align sister chromatids during mitosis; however, mutations do not result in gross aneuploidy.”
BackgroundObeng, E. A., Chappell, R. J., Seiler, M., Chen, M. C., Campagna, D. R., Schmidt, P. J., Schneider, R. K., Lord, A. M., Wang, L., Gambe, R. G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.006 · Cited by 380 · cited 1×
“Moreover, animal models of splicing factor mutations have shown that mutant homozygosity is lethal, whereas in the setting of heterozygosity, the pattern seen inmyeloidmalignancies, further inhibition of the splicing machinery can drive cell death.(18,70) With the intention of exploiting the therapeutic window present…”
BackgroundLee, S. C.-W., Dvinge, H., Kim, E., Cho, H., Micol, J.-B., Chung, Y. R., Durham, B. H., Yoshimi, A., Kim, Y. J., Thomas, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4097 · Cited by 347
Kwok, B., Hall, J. M., Witte, J. S., Xu, Y., Reddy, P., Lin, K., Flamholz, R., Dabbas, B., Yung, A., Al-Hafidh, J., et al. (2015) · Blood · doi:10.1182/blood-2015-08-667063 · Cited by 317
A prognostic score for patients with lower risk myelodysplastic syndrome
Garcia-Manero, G., Shan, J., Faderl, S., Cortes, J., Ravandi, F., Borthakur, G., Wierda, W. G., Pierce, S., Estey, E., Liu, J., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405070 · Cited by 315 · cited 1×
“However, patient outcomes remain highly variable within the subsets defined by these and other prognostic systems.(47) To date, there have been three large studies that have assessed the prognostic impact of MDS-associated gene mutations across a broad cross-section of patients.”
BackgroundChristiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308 · cited 1×
“and are associated with thrombocytopenia, complex karyotype, and a particularly poor prognosis.(10,28)”
BackgroundMutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo
Shirai, C. L., Ley, J. N., White, B. S., Kim, S., Tibbitts, J., Shao, J., Ndonwi, M., Wadugu, B., Duncavage, E. J., Okeyo-Owuor, T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.008 · Cited by 287
Traina, F., Visconte, V, Elson, P., Tabarroki, A., Jankowska, A. M., Hasrouni, E., Sugimoto, Y., Szpurka, H., Makishima, H., O'Keefe, C. L., et al. (2014) · Leukemia · doi:10.1038/leu.2013.269 · Cited by 269
Della Porta, M. G., Gallì, A., Bacigalupo, A., Zibellini, S., Bernardi, M., Rizzo, E., Allione, B., van Lint, M. T., Pioltelli, P., Marenco, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3616 · Cited by 254 · cited 1×
“MDS transplant population, in addition to identifying RUNX1 and ASXL1 as potential markers of poor outcome.(67) Though evaluation of large clinical cohorts and prospective validation is required, these data suggest that genetics may help identify a subset of patients in whom outcomes with standard transplant regimens…”
BackgroundGenetic alterations of the cohesin complex genes in myeloid malignancies
Thota, S., Viny, A. D., Makishima, H., Spitzer, B., Radivoyevitch, T., Przychodzen, B., Sekeres, M. A., Levine, R. L., & Maciejewski, J. P. (2014) · Blood · doi:10.1182/blood-2014-04-567057 · Cited by 249 · cited 1×
“Mutually exclusive loss of function nonsense and frameshift mutations in the cohesin components are found in 11% and 17% of low- and high-risk MDS, respectively.(22,23) Cohesin normally functions to align sister chromatids during mitosis; however, mutations do not result in gross aneuploidy.”
BackgroundMalcovati, L., Papaemmanuil, E., Ambaglio, I., Elena, C., Gallì, A., Della Porta, M. G., Travaglino, E., Pietra, D., Pascutto, C., Ubezio, M., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560227 · Cited by 249 · cited 1×
“For example, analysis of genotype–phenotype relationships has demonstrated that mutations of genes involved in DNAmethylation, cohesin, the RAS pathway, and splicing factors (other than SF3B1) are associated with multilineage dysplasia.(44) Moving forward, although the diagnostic value of single mutations is likely to…”
BackgroundGerstung, M., Pellagatti, A., Malcovati, L., Giagounidis, A., Porta, M. G. D., Jädersten, M., Dolatshad, H., Verma, A., Cross, N. C. P., Vyas, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms6901 · Cited by 238 · cited 1×
“terdependency was also demonstrated in a recent study that combined genetic, cytogenetic, transcriptomic, and hematologic data to predict leukemia-free survival in patients with MDS; in the resulting model, genetics made only a minor contribution to risk estimates.(49) Thus, traditional morphologic and clinical criter…”
ResultCogle, C. R., Craig, B. M., Rollison, D. E., & List, A. F. (2011) · Blood · doi:10.1182/blood-2011-02-337964 · Cited by 222 · cited 1×
“States of 75 cases per 100,000 individuals 65 years of age and older.(2) Over the past decade, DNA sequencing has revolutionized our understanding of”
BackgroundMutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491571 · Cited by 210 · cited 7×
“For example, small-molecule inhibitors of mutant isocitrate dehydrogenase enzymes, present in a minority of patients with MDS, have displayed efficacy in preclinical studies of AML.(68,69) Moreover, animal models of splicing factor mutations have shown that mutant homozygosity is lethal, whereas in the setting of hete…”
BackgroundInfluentialMazumdar, C., Shen, Y., Xavy, S., Zhao, F., Reinisch, A., Li, R., Corces, M. R., Flynn, R. A., Buenrostro, J. D., Chan, S. M., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.09.017 · Cited by 205 · cited 1×
“Instead, recent studies have shown that cohesin mutations can promote transformation by driving aberrant transcriptional programs, potentially by disrupting this complex’s role in stabilizing DNA loops, such as those involved in enhancer-promoter interactions.(25)”
Recent developments in myelodysplastic syndromes
Bejar, R., & Steensma, D. P. (2014) · Blood · doi:10.1182/blood-2014-04-522136 · Cited by 174
Deeg, H. J., Scott, B. L., Fang, M., Shulman, H. M., Gyurkocza, B., Myerson, D., Pagel, J. M., Platzbecker, U., Ramakrishnan, A., Radich, J. P., et al. (2012) · Blood · doi:10.1182/blood-2012-04-423046 · Cited by 160
Ok, C. Y., Patel, K. P., Garcia-Manero, G., Routbort, M. J., Peng, J., Tang, G., Goswami, M., Young, K. H., Singh, R., Medeiros, L. J., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0139-z · Cited by 141 · cited 1×
“Missense TP53 mutations are particularly prevalent among patients with MDS who have undergone chemotherapy, in whom their frequency approaches 40%.(27) These changes often occur alongside loss of the second TP53 allele via deletion of the short arm of chromosome 17”
BackgroundDePersia, A., Godley, L. A., & Churpek, J. E. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12346 · Cited by 128 · cited 1×
“marrow failure syndromes with a propensity to evolve into myeloid malignancies.(11,12,26)”
BackgroundMossner, M., Jann, J.-C., Wittig, J., Nolte, F., Fey, S., Nowak, V., Obländer, J., Pressler, J., Palme, I., Xanthopoulos, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679167 · Cited by 127 · cited 1×
“Moreover, analysis of mutational hierarchies in patients with MDS has identified that mutations in epigenetic regulators, the genes most commonly implicated in clonal hematopoiesis, are founder events, providing additional support that CHIP represents the earliest genetic step in MDS pathogenesis.(34) Given the low ra…”
BackgroundArmand, P. A., Kim, H. T., Rhodes, J. M., Sainvil, M.-M., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., Hearsey, D., Neufeld, E. J., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.09.006 · Cited by 118
Naqvi, K., Jabbour, E. J., Bueso-Ramos, C., Pierce, S. A., Borthakur, G. M., Estrov, Z. E., Ravandi, F., Faderl, S. H., Kantarjian, H. M., & Garcia‐Manero, G. (2011) · Blood · doi:10.1182/blood-2011-03-342642 · Cited by 107
Jadersten, M., Saft, L., Pellagatti, A., Gohring, G., Wainscoat, J. S., Boultwood, J., Porwit, A., Schlegelberger, B., & Hellstrom-Lindberg, E. (2009) · Haematologica · doi:10.3324/haematol.2009.011528 · Cited by 100
Molecular Pathophysiology of Myelodysplastic Syndromes
Lindsley, R. C., & Ebert, B. L. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132436 · Cited by 88 · cited 1×
“A detailed discussion of the functional consequences of these mutations is beyond the scope of this review but has been covered elsewhere.(13,14)”
BackgroundSelf-citationFont, P., Loscertales, J., Benavente, C., Bermejo, A., Callejas, M., Garcia-Alonso, L., Garcia-Marcilla, A., Gil, S., López‐Rubio, M., Martin, E., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1565-4 · Cited by 83 · cited 1×
“However, given this heavy reliance on morphologic assessment, MDS can be challenging to diagnose, with well-documented interobserver variability.(41,42) In light of recent insights into MDS genetics, consideration has been given to the incorporation of mutational data into its diagnostic criteria, similar to the use o…”
BackgroundMossner, M., Jann, J.-C., Nowak, D., Platzbecker, U., Giagounidis, A. A. N., Götze, K. S. S., Letsch, A., Haase, D. T., Shirneshan, K., Braulke, F., et al. (2016) · Leukemia · doi:10.1038/leu.2016.111 · Cited by 76
Takahashi, K., Jabbour, E. J., Wang, X., Luthra, R., Bueso‐Ramos, C. E., Patel, K. P., Pierce, S. A., Yang, H., Wei, Y., Daver, N. G., et al. (2013) · Leukemia · doi:10.1038/leu.2013.165 · Cited by 64
Myelodysplastic Syndromes, Version 2.2015
Greenberg, P. L., Stone, R. M., Bejar, R. L., Bennett, J. M., Bloomfield, C. D., Borate, U., de Castro, C. M., Deeg, H. J., Dezern, A. E., Fathi, A. T., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0038 · Cited by 61 · cited 3×
“Traditionally, therapeutic decision-making in MDS has been guided by individual risk assessment performed using the IPSS or similar tools.(51) Given the central role of somatic mutations in MDS pathogenesis, genetics also holds potential to inform treatment decisions.”
Influential‘CHIP’ping away at clonal hematopoiesis
Link, D. C., & Walter, M. J. (2016) · Leukemia · doi:10.1038/leu.2016.130 · Cited by 58 · cited 1×
“Potential contributors include not only the identity of the CHIP mutation itself but also germline polymorphisms and cell extrinsic factors.(35) In one example of the latter, treatment with chemotherapy has been shown to enable”
BackgroundBravo, G. M., Lee, E., Merchán, B., Kantarjian, H. M., & Garcia‐Manero, G. (2014) · British Journal of Haematology · doi:10.1111/bjh.12957 · Cited by 36 · cited 1×
“A detailed discussion of the functional consequences of these mutations is beyond the scope of this review but has been covered elsewhere.(13,14)”
BackgroundLee, E.-J., & Zeidan, A. M. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1016905 · Cited by 19 · cited 1×
“However, the power of mutational data to predict HMA response is modest at best; in particular, a set of mutations that can identify patients with response rates sufficiently low to justify withholding therapy has not been defined.(63) Moving forward, clarification of the mechanism of action and pharmacokinetics of HM…”
Background
Cited by
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 162
“PD-1/PD-L1 (programmed death receptor 1, programmed death receptor ligand 1) inhibitors play a notable clinical role in B-cell lymphoma, especially in HL. 31 CTLA-4 (cytotoxic T-lymphocyte antigen number 4) inhibitor also demonstrates certain curative effects in patients with HL and AML.”
BackgroundInfluentialFollo, M. Y., Pellagatti, A., Armstrong, R. N., Ratti, S., Mongiorgi, S., De Fanti, S., Bochicchio, M. T., Russo, D., Gobbi, M., Miglino, M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0416-x · Cited by 36
Zha, J., Bi, S., Deng, M., Chen, K., Shi, P., Feng, L., He, J., Pu, X., Guo, C., Zhao, H., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174107 · Cited by 18
Metadata
- Authors
- Kennedy, J. A., & Ebert, B. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-03-20
- Volume
- 35
- Issue
- 9
- Pages
- 968-974
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2590193878
- Cited by
- 170
- References
- 71
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.